Medical Breakthroughs

FDA Clearance vs. Revenue Multiples: The Cardiac AI Reality

Listen to this article · 7 min listen

When a new AI medical device gets FDA clearance, it’s easy to get excited. For investors watching the cardiac monitoring space, that regulatory approval looks like a green light for market entry and seems to take a lot of risk off the table. But there’s a huge difference between being cleared by the FDA and being commercially successful. FDA clearance is a must-have, but it doesn’t guarantee a strong revenue multiple.

The Clearance-to-Reimbursement Chasm

Getting from a cleared medical device to a product that doctors actually use and that generates real revenue is a tough road, especially with healthcare’s weird economics. A 510(k) clearance or a De Novo classification from FDA CDRH just means the device is safe and effective for what it’s supposed to do. That regulatory win doesn’t create a way for anyone to get paid for using it. For investors, the big jump in valuation comes from establishing consistent, predictable reimbursement, not from the regulatory nod itself. Look at AliveCor, a company that’s constantly praised for its long list of FDA clearances. AliveCor got U.S. FDA clearance in January 2026 for its next-gen KAI 12L AI, which lets the Kardia 12L ECG System spot 39 different cardiac conditions. Their whole pitch to investors is built on these regulatory wins, making the tech look validated and ready to go. The problem is, the “revenue multiple question” for AliveCor, or any cardiac AI company, is answered by how those clearances get turned into paid procedures. The Kardia 12L got Category III CPT codes in January 2025 and CMS approved Medicare payment for it in hospital outpatient settings that same year. But if there isn’t a clear, repeatable way for doctors and hospitals to get reimbursed for using a device, even the best-validated SaMD will struggle with adoption and revenue. The revenue multiple is earned in the gap between a cleared product and a reimbursed one. It’s a payment-path exercise before it’s a product exercise.

HeartFlow’s Payer Pathway Precedent

HeartFlow’s path to its IPO in August 2025 is a great example of how a solid payer strategy creates serious valuation, even after they had to kill a SPAC merger in February 2022 because of bad market conditions. HeartFlow’s AI creates 3D models of coronary arteries from CT scans to measure fractional flow reserve (FFR), and their story proves that getting reimbursement is everything. Their ability to go public was tied directly to their success in building a clear reimbursement strategy with specific CPT codes and getting positive coverage decisions. HeartFlow reimbursement coverage details Because of this, clinicians could use HeartFlow’s FFRct analysis in their daily workflow, confident they’d get paid for the service. The tech itself is only part of the story for healthcare AI investors. For doctors to adopt something new, the financial model has to work. HeartFlow’s experience shows that investors will assign big multiples when the commercial plan is proven out, especially the reimbursement part. A strong payer pathway de-risks an investment way more than just a clearance ever could.

iRhythm Technologies: The Scaled Monitoring Benchmark

iRhythm Technologies is the other key case study, showing how ambulatory monitoring revenue can explode once reimbursement is figured out. As the leader in long-term continuous cardiac monitoring with its Zio XT patch, iRhythm has figured out the reimbursement game and achieved massive commercial success. In Q3 2025, iRhythm posted a 30.7% year-over-year revenue jump to $192.9 million and then raised its full-year 2025 guidance to between $735 million and $740 million. Then in Q2 2026, the company reported 20.1% revenue growth and better gross margins. Their story shows that securing that first reimbursement approval is just the beginning. You have to defend and expand it to keep revenue growing. So how’d they do it? iRhythm’s success is built on a mountain of strong clinical evidence that backed up favorable coverage decisions from huge payers, including Medicare. CMS even proposed a 3% rate increase for long-term cardiac monitoring for 2027. The company was able to prove its Zio patch had a better diagnostic yield and was more cost-effective than old-school Holter monitors, which is what locked in their reimbursement status. iRhythm Technologies Medicare coverage policies That, in turn, let them scale up and grab huge market share. For investors, iRhythm proves that once you have stable, consistent reimbursement, you get predictable revenue and massive growth. That scalability, which is directly connected to a clear payment pathway, is what gets you an attractive revenue multiple. The company’s data moat, built from analyzing millions of labeled ECGs, makes it even harder for anyone new to compete with their accuracy or their reimbursement position.

Valuation Conclusion: Reimbursement Earns the Multiple

Looking at these companies side-by-side, the investment thesis for cardiac AI is obvious: the revenue multiple is earned with reimbursement, not just regulatory clearance. FDA clearance gets you in the door, but it’s not nearly enough. For any investor looking at a cleared cardiac monitoring company, the due diligence has to be all about the payment path. The key questions you have to ask are:

  • What CPT codes are they using or going after for this AI service?
  • Have they actually gotten positive coverage decisions from the big commercial payers and from Medicare?
  • How strong is the clinical data showing the AI improves patient outcomes and saves money? That’s what you need to make the case for reimbursement. CMS National Coverage Determinations
  • What’s the strategy for keeping and growing reimbursement as healthcare policy inevitably changes?

So, a company like AliveCor can have a great list of clearances, but its valuation really depends on turning those clearances into consistent, paid-for use. The stories of HeartFlow and iRhythm are proof that in healthcare AI, the road to a big revenue multiple is paved with smart reimbursement strategies. That is what decides who wins. Investors have to look past the regulatory badge and analyze the actual payment mechanics, that’s where the real value is created.

Frequently Asked Questions

Does FDA clearance guarantee commercial success or a high revenue multiple for cardiac monitoring assets?

No, FDA clearance, while essential for market entry, does not automatically translate into commercial viability or a robust revenue multiple. It confirms safety and efficacy but does not establish a payment pathway for the device’s use.

What is the primary factor that drives significant revenue multiples for cleared cardiac monitoring devices?

The primary factor is the establishment of consistent, predictable reimbursement for the device’s use. A clear and established mechanism for providers to be paid for utilizing the technology is critical for widespread adoption and significant revenue generation.

Can you provide an example of a company that achieved a strong valuation due to a defined payer pathway?

HeartFlow’s successful IPO in August 2025 demonstrates how a defined payer pathway can underpin substantial valuation. Their ability to achieve a public listing was linked to their success in establishing a clear reimbursement strategy through specific CPT codes and coverage decisions.

What role does clinical evidence play in securing and maintaining reimbursement for cardiac monitoring technologies?

Robust clinical evidence is crucial for supporting favorable coverage decisions from major payers, including Medicare. Companies like iRhythm Technologies have used clinical evidence to demonstrate improved diagnostic yield and cost-effectiveness, which has been key to securing and solidifying their reimbursement status.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Healthcare AI Investor Guide is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.